Alkermes Plc (ALKS) 45.12 $ALKS
Look for Shares of Alkermes to Potentially Pullback after Yesterday's 1.48% Rise
Comtex SmarTrend(R) - Wed Aug 24, 3:14PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $45.94 to a high of $47.60. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $46.88 on volume of 309,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 45.12 (+0.38)
Alkermes Has Returned 17.8% Since SmarTrend Recommendation (ALKS)
Comtex SmarTrend(R) - Fri Aug 19, 1:59PM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 5 months, Alkermes has returned 17.78% as of today's recent price of $43.96.
ALKS: 45.12 (+0.38)
BioCorRx, Inc. Announces Agreement With Dr. David Gastfriend to Provide Strategic Initiative and Corporate Development Consulting
Marketwire Canada - Wed Aug 17, 7:00AM CDT
LOS ANGELES, CA--(Marketwired - Aug 17, 2016) - BioCorRx, Inc. (OTC PINK: BICX), developer of the BioCorRx® Recovery Program, a Medication-Assisted Treatment (MAT) program, announces a consulting and advisory agreement with David R. Gastfriend, M.D. The agreement with Dr. Gastfriend is part of the Company's continued drive to expand core business development capabilities and regulatory support infrastructure. Dr. Gastfriend will facilitate potential strategic directions and partnerships as well as provide situation specific expertise to the Company with regard to regulatory approval processes.
ALKS: 45.12 (+0.38)
25.5% Return Seen to Date on SmarTrend Alkermes Call (ALKS)
Comtex SmarTrend(R) - Fri Aug 12, 1:07AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 4 months, Alkermes has returned 25.46% as of today's recent price of $46.82.
ALKS: 45.12 (+0.38)
Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA(R) for Treatment of Schizophrenia
BusinessWire - Mon Aug 08, 6:00AM CDT
---- Notice of Allowance Issued for ARISTADA Patent Application, Extending Expected Protection Into 2035 --
ALKS: 45.12 (+0.38)
Alkermes Has Returned 32.4% Since SmarTrend Recommendation (ALKS)
Comtex SmarTrend(R) - Thu Aug 04, 1:10PM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 4 months, Alkermes has returned 32.45% as of today's recent price of $49.43.
ALKS: 45.12 (+0.38)
Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 10:06AM CDT
Alkermes (ALKS) reported a narrower-than-expected, second-quarter 2016 loss while revenues beat estimates; the company revised its outlook for 2016.
INVA: 11.09 (+0.02), FCSC: 0.89 (-0.01), ANIP: 59.86 (-1.56), ALKS: 45.12 (+0.38)
Alkermes Falls 7.07% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 28, 2:59PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $47.23 to a high of $51.50. Yesterday, the shares fell 7.1%, which took the trading range below the 3-day low of $49.28 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALKS: 45.12 (+0.38)
Alkermes plc Reports Second Quarter 2016 Financial Results
BusinessWire - Thu Jul 28, 6:00AM CDT
---- Company Improves Financial Expectations for 2016 Driven by Strong VIVITROL(R) Performance --
ALKS: 45.12 (+0.38)
38.7% Return Seen to Date on SmarTrend Alkermes Call (ALKS)
Comtex SmarTrend(R) - Thu Jul 28, 12:28AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 4 months, Alkermes has returned 38.75% as of today's recent price of $51.78.
ALKS: 45.12 (+0.38)
After Yesterday's Rally of 3.42% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 22, 3:05PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $41.29 to a high of $44.00. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $42.81 on volume of 339,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 45.12 (+0.38)
Alkermes' Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Wed Jun 01, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016, at 1:20 p.m. PDT (4:20 p.m. EDT/9:20 p.m. BST) from the Terranea Resort in Rancho Palos Verdes, Calif. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 45.12 (+0.38)
Shares of ALKS Up 24.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jun 01, 1:09AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 2 months, Alkermes has returned 24.36% as of today's recent price of $46.41.
ALKS: 45.12 (+0.38)
SmarTrend Watching for Potential Pullback in Shares of Alkermes After 1.89% Gain
Comtex SmarTrend(R) - Tue May 31, 4:34PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $45.99 to a high of $47.90. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $46.21 on volume of 692,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 45.12 (+0.38)
Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07), ALKS: 45.12 (+0.38)
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors
BusinessWire - Thu May 26, 6:00AM CDT
Alkermes plc (NASDAQ: ALKS) today announced the appointment of Nancy L. Snyderman, M.D., to the company's Board of Directors. Dr. Snyderman most recently served as Chief Medical Editor at NBC News, and has more than three decades of experience as a leading voice in healthcare and medicine. Dr. Snyderman is a board certified Otolaryngologist-Head and Neck Surgeon and Fellow in the American College of Surgeons.
ALKS: 45.12 (+0.38)
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230
BusinessWire - Wed May 25, 6:00AM CDT
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell Activator (SECA(TM)) protein designed for targeted interleukin-2 (IL-2) receptor activation. The multi-center phase 1 study is designed to evaluate the safety, tolerability and immunological-pharmacodynamic effects of ALKS 4230 in the treatment of patients with solid tumors.
ALKS: 45.12 (+0.38)
Look for Shares of Alkermes to Potentially Pullback after Yesterday's 1.48% Rise
Comtex SmarTrend(R) - Wed Aug 24, 3:14PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $45.94 to a high of $47.60. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $46.88 on volume of 309,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 45.12 (+0.38)
Alkermes Has Returned 17.8% Since SmarTrend Recommendation (ALKS)
Comtex SmarTrend(R) - Fri Aug 19, 1:59PM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 5 months, Alkermes has returned 17.78% as of today's recent price of $43.96.
ALKS: 45.12 (+0.38)
BioCorRx, Inc. Announces Agreement With Dr. David Gastfriend to Provide Strategic Initiative and Corporate Development Consulting
Marketwire Canada - Wed Aug 17, 7:00AM CDT
LOS ANGELES, CA--(Marketwired - Aug 17, 2016) - BioCorRx, Inc. (OTC PINK: BICX), developer of the BioCorRx® Recovery Program, a Medication-Assisted Treatment (MAT) program, announces a consulting and advisory agreement with David R. Gastfriend, M.D. The agreement with Dr. Gastfriend is part of the Company's continued drive to expand core business development capabilities and regulatory support infrastructure. Dr. Gastfriend will facilitate potential strategic directions and partnerships as well as provide situation specific expertise to the Company with regard to regulatory approval processes.
ALKS: 45.12 (+0.38)
25.5% Return Seen to Date on SmarTrend Alkermes Call (ALKS)
Comtex SmarTrend(R) - Fri Aug 12, 1:07AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 4 months, Alkermes has returned 25.46% as of today's recent price of $46.82.
ALKS: 45.12 (+0.38)
Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA(R) for Treatment of Schizophrenia
BusinessWire - Mon Aug 08, 6:00AM CDT
---- Notice of Allowance Issued for ARISTADA Patent Application, Extending Expected Protection Into 2035 --
ALKS: 45.12 (+0.38)
Alkermes Has Returned 32.4% Since SmarTrend Recommendation (ALKS)
Comtex SmarTrend(R) - Thu Aug 04, 1:10PM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 4 months, Alkermes has returned 32.45% as of today's recent price of $49.43.
ALKS: 45.12 (+0.38)
Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 10:06AM CDT
Alkermes (ALKS) reported a narrower-than-expected, second-quarter 2016 loss while revenues beat estimates; the company revised its outlook for 2016.
INVA: 11.09 (+0.02), FCSC: 0.89 (-0.01), ANIP: 59.86 (-1.56), ALKS: 45.12 (+0.38)
Alkermes Falls 7.07% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 28, 2:59PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $47.23 to a high of $51.50. Yesterday, the shares fell 7.1%, which took the trading range below the 3-day low of $49.28 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALKS: 45.12 (+0.38)
Alkermes plc Reports Second Quarter 2016 Financial Results
BusinessWire - Thu Jul 28, 6:00AM CDT
---- Company Improves Financial Expectations for 2016 Driven by Strong VIVITROL(R) Performance --
ALKS: 45.12 (+0.38)
38.7% Return Seen to Date on SmarTrend Alkermes Call (ALKS)
Comtex SmarTrend(R) - Thu Jul 28, 12:28AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 4 months, Alkermes has returned 38.75% as of today's recent price of $51.78.
ALKS: 45.12 (+0.38)
After Yesterday's Rally of 3.42% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 22, 3:05PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $41.29 to a high of $44.00. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $42.81 on volume of 339,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 45.12 (+0.38)
Alkermes' Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Wed Jun 01, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016, at 1:20 p.m. PDT (4:20 p.m. EDT/9:20 p.m. BST) from the Terranea Resort in Rancho Palos Verdes, Calif. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 45.12 (+0.38)
Shares of ALKS Up 24.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jun 01, 1:09AM CDT
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 2 months, Alkermes has returned 24.36% as of today's recent price of $46.41.
ALKS: 45.12 (+0.38)
SmarTrend Watching for Potential Pullback in Shares of Alkermes After 1.89% Gain
Comtex SmarTrend(R) - Tue May 31, 4:34PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $45.99 to a high of $47.90. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $46.21 on volume of 692,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 45.12 (+0.38)
Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07), ALKS: 45.12 (+0.38)
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors
BusinessWire - Thu May 26, 6:00AM CDT
Alkermes plc (NASDAQ: ALKS) today announced the appointment of Nancy L. Snyderman, M.D., to the company's Board of Directors. Dr. Snyderman most recently served as Chief Medical Editor at NBC News, and has more than three decades of experience as a leading voice in healthcare and medicine. Dr. Snyderman is a board certified Otolaryngologist-Head and Neck Surgeon and Fellow in the American College of Surgeons.
ALKS: 45.12 (+0.38)
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230
BusinessWire - Wed May 25, 6:00AM CDT
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell Activator (SECA(TM)) protein designed for targeted interleukin-2 (IL-2) receptor activation. The multi-center phase 1 study is designed to evaluate the safety, tolerability and immunological-pharmacodynamic effects of ALKS 4230 in the treatment of patients with solid tumors.
ALKS: 45.12 (+0.38)
